Company 2018-09-06T10:41:46+00:00

Our Mission

Advance next-generation sequencing and precision medicine through rapid and high quality targeted sequencing 

At Paragon Genomics, we develop and commercialize rapid, easy-to-use, ultra-high multiplex PCR-based target enrichment solutions for Next-Generation Sequencing (NGS). Our proprietary CleanPlex® background-removing technology enables NGS customers to develop targeted sequencing assays that are accurate, sensitive, and simple, yet cost effective. Our technology is applicable to many fast-growing NGS segments such as cancer research, liquid biopsy, biomarker discovery, genomics-guided breeding, companion diagnostics, and immunotherapy monitoring.

Who We Are

At Paragon Genomics, we are a passionate group dedicated to providing cutting-edge technologies and solutions for the global genomic research and application community.  Our goal is to move precision medicine forward. The team is composed of industry veterans and academic experts who previously worked with well-known industry leading companies and institutions such as Affymetrix, Novartis, Applied Biosystems, Siemens Healthcare, Stanford and Harvard.

Paragon Genomics’ leadership team proudly graduated from the California Life Sciences Institute’s (CLSI) Spring 2016 FAST Advisory Program. 

Leadership Team

Tao Chen, MBA
Co-Founder and CEO

Zhitong Liu, PhD
Co-Founder and CTO

Guoying Liu, PhD
Bioinformatics

Jeffrey Liu
R&D and Operations

Bruce Simmons
Business Development

Dawn Casey
Business Operations

Edward Jan, PhD
Product Marketing

Cassie Larson
Human Resources

Team

Advisors

Rodney Turner
CEO, AYOXXA Biosystems GmbH

Jin Billy Li, PhD
Associate Professor, Stanford University

Joe Keegan, PhD
Director, Interpace Diagnostics

Investors